Abstract:Abstract Background: Sarcoma is a malignant cancer that arises from transformed cells of mesenchymal origin. Sarcoma has the characteristics of low incidence and wide distribution of onset age. Sarcoma patients have poor prognosis and very limited selection of approved targeted drugs. Till now, the genomic features of sarcoma patients in China have not been well understood. Here we present the comprehensive genomic features of 202 sarcoma patients and compared mutations in different subtypes of sarcomas. Methods: Deep sequencing targeting 450 cancer genes was performed on FFPE and matched blood samples collected from 202 sarcoma patients. Based on the histology patients included 33 osteosarcoma (OS), 24 rhabdomyosarcoma (RMS), 20 liposarcoma (LPS), 19 fibrosarcoma (FBS), 16 leiomyosarcoma (LMS), 14 Ewing’s sarcoma (ES), 11 hemangiosarcoma (HMS), 10 synovial sarcoma (SS), 9 chondrosarcoma (CDS), and 46 others in this study. Genomic alterations (GAs) including single nucleotide variants (SNVs), insertions and deletions, copy number variations (CNV) and fusions were assessed. Results: Based on the deep sequencing results, there are 1219 somatic mutations detected in all 202 sarcomas, average 6.0 mutations per sample. The most common GAs of LPS, ES and SS’s are consistent with those mentioned in NCCN guidelines (MDM2 55%, EWSR1 78.6% and SS18 80%, respectively). OS, RMS and LMS shared the same most common GAs of TP53 (25%-50%). The second ranked common GAs were NCOR1 (24%), FRS2 (20.8%), ATRX (25%) genes, and the third ranked GAs were RB1 (24%), CDK4 (16.7%) and MAP2K4 (25%) genes. 161/202 patients (79.7%) harbored at least one actionable mutations which might benefit from FDA approved drugs or drugs were under investigation in clinical trials. All FBS, 93.8% LMS and 90.9% HMS have actionable mutations, however, only 10% SS and 35.7% ES have actionable mutations. 8 samples have CNV (including MDM2/4, EGFR and CCND1) which was related to hyper-progression of immunotherapy. All these 8 samples were bone tumor including 4 OS, 1 CDS, 2 ES and 1 fibrosarcoma of bone. Conclusions: Through the comprehensive genomic profiling, different types of sarcomas showed different characteristics of genomic alterations, and potential therapeutic targets may be identified for the patients. Further, NGS provides information on whether or not patients may have the potential hyper-progression of immunotherapy. Citation Format: Xinghua Song, Zuping Lian, YanBin Xiao, Kunpeng Bu, Ye Qiu, Tao Ji, Dan Liu, Angen Liu, Kai Wang. Comparison of mutations in different subtypes of sarcomas and its clinical implications [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3421.

Additional File 2: of Targeted Next Generation Sequencing Identified Clinically Actionable Mutations in Patients with Esophageal Sarcomatoid Carcinoma

Additional File 2 of A Genomic-Clinicopathologic Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Gastric Cancer

Prevalence of Gene Amplifications of Sox-2, C-Met, and Fgfr1 in Asian Patients with Esophageal Squamous Cell Carcinoma.

Corrigendum: Genome-wide Association Study of Esophageal Squamous Cell Carcinoma in Chinese Subjects Identifies Susceptibility Loci at PLCE1 and C20orf54

Abstract 3421: Comparison of Mutations in Different Subtypes of Sarcomas and Its Clinical Implications

Table S2 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Additional File 2 of Genetic Alteration of Chinese Patients with Rectal Mucosal Melanoma

Comprehensive Genomic Profiling of Sarcomas in Chinese Population.

Additional File 2 of Identification and Validation of a Six-Gene Signature Associated with Glycolysis to Predict the Prognosis of Patients with Cervical Cancer

Additional File 8 of the Immune Subtypes and Landscape of Sarcomas

Molecular characteristics and multivariate survival analysis of 43 patients with locally advanced or metastatic esophageal squamous cell carcinoma

Genetic Alterations in Esophageal Tissues from Squamous Dysplasia to Carcinoma.

Supplementary Tables 1-2, Figures 1-2 from Distinctive MicroRNA Profiles Relating to Patient Survival in Esophageal Squamous Cell Carcinoma

Gene mutations of esophageal squamous cell carcinoma based on next-generation sequencing

Genomic alterations in two patients with esophageal carcinosarcoma identified by whole genome sequencing: a case report

Whole-genome sequencing of 508 patients identifies key molecular features associated with poor prognosis in esophageal squamous cell carcinoma

Characteristics and response to Next‐generation sequencing‐guided therapy in locally advanced or metastatic esophageal cancer

Prognostic Implications of Six Altered Genes in Asian Non-Surgical Esophageal Carcinoma Patients Treated with Chemoradiotherapy

MOESM2 of Molecular Analysis of Cell-Free DNA Identifies Distinct Molecular Features in Patients with Chemosensitive and Chemorefractory Small Cell Lung Cancer

Additional File 3 of Identification of RNA-splicing Factor Lsm12 As a Novel Tumor-Associated Gene and a Potent Biomarker in Oral Squamous Cell Carcinoma (OSCC)

Genomic Analyses Reveal Mutational Signatures and Frequently Altered Genes in Esophageal Squamous Cell Carcinoma